Marsela Braunstein

It is widely considered that combination treatment is a cornerstone of cancer therapy. Therefore, this workshop will examine strategies for rational combination approaches in radioligand therapy to maximize therapeutic efficacy while minimizing toxicity. We will explore the biological rationale for pairing RLT with DDR inhibitors, immune checkpoint inhibitors, and emerging immunotherapies, including CAR-T cells. By leveraging the unique DNA-damaging properties of alpha and beta emitters, alongside agents such as DDR inhibitors, we can enhance tumor susceptibility and exploit synergistic mechanisms that amplify tumor cell killing beyond monotherapy. Join this session to guide optimal combination strategies and improve patient outcomes.

Discussion Points:

• How to minimize toxicity whilst also minimizing radiopharmaceutical dose – but
• improve efficacy?
• Establishing the timings of combination therapies – preclinical strategies to understand optimal combination partners
• Overcoming tumor resistance and sensitizing tumors to treatment
• Biomarker-driven patient selection – choosing patients most likely to benefit from specific RLT combinations